Intelligencia AI (intelligencia.ai) is a New York-based health tech company founded in 2017 that applies machine learning and curated biomedical data to clinical drug development. The company markets its platform under the EntelligenceAI brand as an intelligent partner for pharmaceutical teams. It curates and harmonizes over 1.5 billion data points spanning clinical trial design, regulatory designations, biological pathways, gene expression, and funding data to power its models. The flagship product, Portfolio Optimizer, is a patented SaaS tool that delivers AI-driven Probability of Technical and Regulatory Success (PTRS) assessments for interventional, FDA-track clinical trials. The platform claims 80% prospective and 91% retrospective accuracy in predicting whether a drug candidate will reach FDA approval. Users can assess PTRS across clinical phases and receive explainability outputs to support investment and development decisions. Beyond PTRS, the suite includes Asset Optimizer for evaluating clinical trial design parameters and identifying additional indications, BD&L Navigator for rapidly screening and prioritizing external licensing or acquisition assets, and Dynamic Benchmarks for benchmarking clinical success rates with dual-phase and non-linear progression models. Custom bespoke insights projects are also offered through a professional services team. The primary customer base is mid-to-large pharmaceutical and biotechnology companies as well as venture capitalists and hedge fund managers who need to quantify the risk of drug pipeline assets. The company employs approximately 110 people globally, with offices in New York and Athens, Greece, was named to the Inc. 5000 list in 2025, and won the 2025 Artificial Intelligence Excellence Award from the Business Intelligence Group. Key features: - AI-driven Probability of Technical and Regulatory Success (PTRS) assessments with 80% prospective accuracy - Portfolio Optimizer SaaS: phase transition predictions and explainability for FDA-track trials - Asset Optimizer: clinical trial design parameter evaluation and indication expansion analysis - BD&L Navigator: external asset identification and prioritization for business development - Dynamic Benchmarks: non-linear, dual-phase clinical success rate benchmarking - Over 1.5 billion curated and harmonized clinical and biological data points underpinning all models - Bespoke Insights: custom project services for tailored data extraction and analysis
Pricing Information for EntelligenceAI Pricing details for the AI agent "EntelligenceAI" from "Intelligencia AI" are not available.